BasilioColligris, Jesús Pintor
178
90.
Barnes TM, Hou J, King BM. Chimeric IL-1 receptor type I agonists and
antagonists.WO2012016203 (2012)
91.
Furfine ES, Hou J, Collins K, et al., editors. EBI-005: an Interleukin-1Receptor
Inhibitor Designed for the Treatment of Dry Eye Syndrome, 2012 Poster:
2340/A3572012.
92.
SoA, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in
acute gout.
Arthritis Res Ther.
9
(2), R28 (2007).
93.
Fel A, Aslangul E, Le Jeunne C. (Eye and corticosteroid's use).
Presse Med.
41
(4), 414-21 (2012).
94.
Carracedo G, Peral A, Pintor J. Diadenosine polyphosphates in tears of Sjogren
syndrome patients.
InvestOphthalmol Vis Sci.
51
(11), 5452-9 (2010).
95.
Pintor J. (Amolecular marker for dry eye).
Arch Soc Esp Oftalmol.
82
(3), 129-
30 (2007).
96.
McGinnigle S, Naroo SA, Eperjesi F. Evaluation of dry eye.
Surv Ophthalmol.
57
(4), 293-316 (2012).
97.
Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and
management of dry eye disease.
Am JOphthalmol.
151
(5), 792-8 e1 (2011).
